[1]Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22(3):436-445. doi:10.1101/gr.133645.111
[2]Zhang Kai, Chen Huajun, Wang Ye, et al. Clinical characteristics and molecular patterns of RET-rearranged lung cancer in Chinese patients. Oncol Res, 2019, 27(5): 575-582. doi: 10.3727/096504018X153449792 53618
[3]Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol, 2018, 13(10): 1595-1601. doi:10.1016/j.jtho.2018.07.004
[4]2022版CSCO非小细胞肺癌诊疗指南
[5] Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Retrieved Dec 16, 2020
https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/
[6] Zhou Q, et al. 2021 WCLC. Abs. MA02.02.
[7] Besse B, et al. Updated efficacy and safety data from the Phase 1/2 ARROW study of pralsetinib in patients(pts) with advanced RET fusion non-small cell lung cancer (非小细胞肺癌) . 2022 ESMO abstr 1170P.
[8] Offin M, Guo R, Wu SL, et al. Immunophenotype and response to immunotherapy of RET-rearranged lung cancers. JCO Precis Oncol, 2019, 3: PO.18.00386. doi: 10.1200/PO.18.0038
[9]Dudnik E, Bshara E, Grubstein A, et al. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune checkpoint inhibitors (ICPi). Lung Cancer, 2018, 124: 117-124. doi: 10.1016/j.lungcan.2018.07.044